An Follow-up Study of Occlusal Adjustment for Orofacial Pain

Trigeminal Neuralgia Clinical Trial

Official title:

An Follow-up Study of Occlusal Adjustment for Orofacial Pain

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02856906
• Other study ID #: Department of Oral Anatomy
• Status: Recruiting
• Phase: N/A
• Start date: August 2016
• Est. completion date: December 2025

Study information

• Verified date: February 2024
• Source: Air Force Military Medical University, China
• Contact: Shaoxiong Guo, M.D
• Phone: 8615902969892
• Email: xiongshao1989[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether what kind of occlusion are related the orofacial pain under investigation, and whether occlusal adjustment have an effect in relief of this kind of orofacial pain.

Description:

1. T-scan analysis system is used to record the occlusal contact relationships. And at same time, Electromyographic recording system is used to record the Masseter (MM) and Anterior Temporalis (TA) muscles' surface electromyographic (SEMG) in the two time points: before the treatment and 4-weeks follow-up after treatment.

After recording, several parameters is taken to indicate the occlusal changes when researchers set the T-Scan occlusal parameters as 100% intercuspal position (ICP) maximum voluntary clenching (MVC), 75% ICP-MVC, 50% ICP-MVC, 25% ICP-MVC, and the number of occlusal contact and the values of the the Masseter (MM) and Anterior Temporalis (TA) muscles' surface electromyographic (SEMG) values is acquired by the software in the screen.

2. Occlusal imprints which indicates the their occlusal relationships is made by researchers when the volunteers ICP clenching in the two time points: before the treatment and 4-weeks follow-up after treatment.

Break-over and the sub-break-over point of the occlusal imprints is amplified by software. The investigators compute the number and area about that.

3. The investigators also recorded frequency of attack and score of visual analogue scale (VAS), the dosage of drug, and short form-McGill-2 in the follow-ups time frame: immediately after the first treatment, 1-, 4-, 12- and 24-weeks after treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 2025
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• The patients claim orofacial pain. The pain has been treated but not relieved by medication, surgery, root canal therapy, even teeth extracting, or the pain relieve effect went down for a period. The patients also match the following item 1 or 2:

• Item 1: disorder characterized by recurrent unilateral brief electric shock-like pains, abrupt in onset and termination, limited to the distribution of one or more divisions of the trigeminal nerve and triggered by innocuous stimuli. It may develop without apparent cause or be a result of another diagnosed disorder. There may or may not be, additionally, persistent background facial pain of moderate intensity.They fulfilled criteria A-E

• At least three attacks of unilateral facial pain fulfilling criteria B and C

• Occurring in one or more divisions of the trigeminal nerve, with no radiation beyond the trigeminal distribution

• Pain has at least three of the following four characteristics:

• recurring in paroxysmal attacks lasting from a fraction of a second to 2 minutes.

• severe intensity.

• electric shock-like, shooting, stabbing or sharp in quality.

• precipitated by innocuous stimuli to the affected side of the face.

• No clinically evident neurological deficit

• Not better accounted for by another the International Classification of Headache Disorders 3rd edition diagnosis.

• Item 2 Persistent facial and/or oral pain, with varying presentations but recurring daily for more than 2 hours per day over more than 3 months, in the absence of clinical neurological deficit.They fulfilled criteria A-E

• Facial and/or oral pain fulfilling criteria B and C

• Recurring daily for >2 hours per day for >3 months

• Pain has both of the following characteristics: 1. poorly localized, and not following the distribution of a peripheral nerve 2. Dull, aching or nagging quality

• Clinical neurological examination is normal

• A dental cause has been excluded by appropriate investigations

• Not better accounted for by another the International Classification of Headache Disorders 3rd edition diagnosis

Exclusion Criteria:

• Head and facial trauma; orofacial and/or intracranial space occupying lesion indicated by craniofacial CT ; pain caused by sinusitis and acute pulpitis, periapical periodontitis and periodontitis disease; no occlusal abnormalities and occlusion treatment indications through a series of occlusal examination; children (younger than 18 years old) and pregnant women.

Related Conditions & MeSH terms

• Facial Pain
• Neuralgia
• Orofacial Pain
• Trigeminal Neuralgia

Intervention

Other:
• occlusal adjustment

Locations

Country	Name	City	State
China	State Key Laboratory of Military Stomatology, Department of Oral Anatomy and Physiology and TMD,School of Stomatology, The Fourth Military Medical University, Xi 'an, China.	Xi'an	Shaanxi

Sponsors (1)

Lead Sponsor	Collaborator
Meiqing Wang

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Number of break-over point of occlusal imprints.		4-weeks after treatment
Other	Number of sub-break-over point of occlusal imprints.		4-weeks after treatment
Other	Area of break-over point of occlusal imprints(cm2) .	Area of break-over point of occlusal imprints(cm2) is computed by software.	4-weeks after treatment
Other	Area of sub-break-over point of occlusal imprints(cm2).	Area of sub-break-over point of occlusal imprints(cm2) is computed by software.	4-weeks after treatment
Other	Occlusal force ratio(%)in position (ICP)- maximum voluntary clenching (MVC).	The T-scan analysis system indicates the value of left and right side occlusal force ratio(%)in position (ICP)- maximum voluntary clenching (MVC).	4-weeks after the treatment
Other	Number of occlusal contact in T-Scan system in ICP-MVC	The T-scan analysis system indicates the number of left and right side occlusal contact in ICP-MVC.	4-weeks after the treatment
Other	Anterior Temporalis (TA) muscles' surface electromyographic(SEMG)(uV) in ICP-MVC.	The system indicates left and right side Anterior Temporalis (TA) muscles' surface electromyographic(SEMG) (uV)in ICP-MVC.	4-weeks after the treatment
Other	Masseter (MM) surface electromyographic(SEMG)(uV)in ICP-MVC.	The system indicates right and left side Masseter (MM) surface electromyographic(SEMG)(uV)in ICP-MVC.	4-weeks after the treatment
Other	Occlusal force ratio(%)of dental arch in lateral cuspal to cuspal.	T-scan analysis system indicates the value of working and non-working side dental arch occlusal force ratio(%) in lateral cuspal to cuspal.	4-weeks after treatment
Other	Number of occlusal contact in lateral cuspal to cuspal	T-scan analysis system indicates number of occlusal contact of working and non-working side in lateral cuspal to cuspal.	4-weeks after treatment
Other	Anterior Temporalis (TA) muscles' surface electromyographic(SEMG)(uV) in lateral cuspal to cuspal.	The system indicates working and non-working side Anterior Temporalis (TA) muscles' surface electromyographic(SEMG)(uV)in lateral cuspal to cuspal.	4-weeks after treatment
Other	Masseter (MM) surface electromyographic(SEMG)(uV)in lateral cuspal to cuspal.	The system indicates non-working and working side Masseter (MM) surface electromyographic(SEMG)(uV)in lateral cuspal to cuspal.	4-weeks after treatment
Primary	Pain reduction assessed on the Visual Analog Scale(VAS)		4-weeks after the treatment
Secondary	Pain reduction assessed on the Visual Analog Scale(VAS)		1-, 12-, 24-weeks after the treatment
Secondary	Attack frequency	Times of attack per day stand for attack frequency	1-,4-,12-,24-weeks after the treatment
Secondary	Pain reduction assessed on the short form-McGill-2	Pain' levels reduction assessed on score of short form-McGill-2 .	1-,4-,12-,24-weeks after the treatment
Secondary	The dosage of medicine	Grams per day of patients take the medicine .	1-, 4-, 12-, 24-weeks after the treatment.